Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

Mortality Risk May Be Higher in People With OCD
News
Mortality Risk May Be Higher in People With OCD
02/01/2024
People with obsessive-compulsive disorder (OCD) may have a higher risk of mortality, both all-cause and due to natural causes, than individuals without OCD, according to recent population-based cohort study results published in The BMJ.
People with obsessive-compulsive disorder (OCD) may have a higher risk of mortality, both all-cause and due to natural causes, than individuals without OCD, according to recent population-based cohort study results published in The BMJ.
People with obsessive-compulsive...
02/01/2024
Psych Congress Network
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
Study Reveals Significant Cognitive Impairment in Patients With MDD
News
Study Reveals Significant Cognitive Impairment in Patients With MDD
01/31/2024
Individuals with major depressive disorder may have significant moderate cognitive deficits in executive function, memory, and attention, when compared to healthy subjects. Researchers published their findings in Psychotherapy and...
Individuals with major depressive disorder may have significant moderate cognitive deficits in executive function, memory, and attention, when compared to healthy subjects. Researchers published their findings in Psychotherapy and...
Individuals with major...
01/31/2024
Psych Congress Network

Advertisement

Hearing Loss Prevention Could Delay, Prevent Dementia Onset
News
Hearing Loss Prevention Could Delay, Prevent Dementia Onset
01/29/2024
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or...
01/29/2024
Psych Congress Network
a doctor holds a generic orange pill bottle
News
Zenzedi CII 30 mg Tablets Recalled Over Mislabeling Concerns
01/29/2024
zurity Pharmaceuticals, Inc. has issued a voluntary recall of 1 lot of Zenzedi CII 30 mg tablets after a Nebraska pharmacist discovered carbinoxamine maleate, an antihistamine, in a bottle labeled as Zenzedi 30 mg.
zurity Pharmaceuticals, Inc. has issued a voluntary recall of 1 lot of Zenzedi CII 30 mg tablets after a Nebraska pharmacist discovered carbinoxamine maleate, an antihistamine, in a bottle labeled as Zenzedi 30 mg.
zurity Pharmaceuticals, Inc. has...
01/29/2024
Neurology
News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional

Advertisement

FDA
News
FDA Preliminary Evaluation Finds No Clear Link Between GLP-1 Drugs and Suicidal Thoughts, Cautions on Small Risk
01/26/2024
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation...
01/26/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Gray Matter Reduced in Patients With Early-Onset Psychosis
01/23/2024
Patients with early-onset psychosis had significantly lower volume of gray matter in their brains compared with healthy control subjects, according to study findings published in Molecular Psychiatry.
Patients with early-onset psychosis had significantly lower volume of gray matter in their brains compared with healthy control subjects, according to study findings published in Molecular Psychiatry.
Patients with early-onset...
01/23/2024
Psych Congress Network

Advertisement

two profiles of people in illustrated style
News
Once-Weekly Oral Risperidone Comparable to Daily Risperdal for Schizophrenia
01/16/2024
Oral risperidone (LYN-005) administered once a week shares a comparable pharmacokinetic profile with immediate-release oral Risperdal taken daily in adult patients living with schizophrenia.
Oral risperidone (LYN-005) administered once a week shares a comparable pharmacokinetic profile with immediate-release oral Risperdal taken daily in adult patients living with schizophrenia.
Oral risperidone (LYN-005)...
01/16/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use